Neuroprotective and neurotoxic properties of the 'inert' gas, xenon

Abstract

Background. Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors have been shown not only to have neuroprotective effects but also to exhibit neurotoxic properties. In this study, we used c-Fos, a protein product of an immediate early gene, as a marker of neuronal injury to compare the neuroprotective effects of xenon and the neurotoxic properties of xenon, nitrous oxide, and ketamine, three anaesthetics with NMDA receptor antagonist properties. Methods. We used an in vivo rat model of brain injury in which N-methyl-DL-aspartic acid (NMA) is injected subcutaneously (s.c.) and c-Fos expression in the arcuate nucleus is used as a measure of injury. To examine the neurotoxic potential of each of the three anaesthetics with NMDA receptor antagonist properties, c-Fos expression in the posterior cingulate and retrosplenial (PC/RS) cortices was measured. Results. Xenon dose-dependently suppressed NMA-induced c-Fos expression in the arcuate nucleus with an IC50 of 47 (2)% atm. At the highest concentration tested (75% atm) NIVIA-induced neuronal injury was decreased by as much as that observed with the prototypical NMIDA antagonist MK801 (0.5 mg kg-1 s.c.). Both nitrous oxide and ketamine dose-dependently increased c-Fos expression in PORS cortices; in contrast xenon produced no significant effect. If the dopamine receptor antagonist haloperidol was given before either nitrous oxide or ketamine, their neurotoxic effects were eliminated. Conclusions. Uniquely amongst anaesthetics with known NMIDA receptor antagonist action, xenon exhibits neuroprotective properties without co-existing neurotoxicity. The reason why ketamine and nitrous oxide, but not xenon, produce neurotoxicity may involve their actions on dopaminergic pathways.